SCHEDULE 13G/A: Redmile Group Discloses 6.2% Passive Stake in Immunome, Inc.

Investment firm Redmile Group, LLC, along with its principal Jeremy C. Green, has disclosed a passive beneficial ownership of 6.2% in Immunome, Inc., totaling 5,361,187 shares of common stock.

Summary

• Redmile Group, LLC, and its principal Jeremy C. Green, have reported a beneficial ownership of 5,361,187 shares of Immunome, Inc. common stock.
• This stake represents 6.2% of Immunome, Inc.'s outstanding common stock.
• The shares are held by private investment vehicles managed by Redmile Group, LLC, including Redmile Biopharma Investments III, L.P., which directly owns 3,879,415 shares (4.5%).
• The percentage ownership is calculated based on 86,950,655 shares of common stock outstanding as of March 14, 2025, as reported by Immunome, Inc. in its Form 10-K.
• The filing indicates a passive investment purpose, explicitly stating the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a reputable institutional investor like Redmile Group is generally viewed as a positive signal, indicating confidence in the company's long-term prospects, even if it's a routine regulatory filing.

Positives

• A significant institutional investor, Redmile Group, LLC, has disclosed a substantial passive stake, indicating potential confidence in Immunome, Inc.'s long-term prospects.
• The investment is held by multiple entities under Redmile Group's management, demonstrating a coordinated investment strategy.

Risks

• The document itself does not detail specific risks related to Immunome, Inc.'s business operations or financial performance, as it is a disclosure of ownership.

Future Outlook

This Schedule 13G filing does not provide any forward-looking statements or guidance regarding Immunome, Inc.'s future outlook.

Management Comments

• The document contains certifications from Redmile Group, LLC and Jeremy C. Green stating that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing indicates continued institutional investor interest in the biotechnology sector, specifically in Immunome, Inc., a company focused on antibody discovery and development. The passive nature of the stake suggests a long-term investment perspective rather than an activist one.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory requirement for investors acquiring more than 5% of a company's stock with a passive intent.
• The disclosed stake of 6.2% by Redmile Group, LLC is a significant position for an institutional investor in a biotechnology company like Immunome, Inc., comparable to other institutional holdings seen in similar-sized biopharma firms.
• No specific comparable companies, projects, or results are mentioned in this filing.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 6.2% stake may increase investor confidence and potentially influence stock valuation.
• Management: Awareness of a large passive shareholder may influence strategic decisions, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

Immunome Inc, Redmile Group, Jeremy C. Green, Redmile Biopharma Investments III, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, biotechnology, biopharma